Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ketosis × eribulin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 108 Triple Negative Breast Neoplasms 24 Neoplasm Metastasis 14 Ovarian Neoplasms 4 Brain Neoplasms 4 Neoplasms 3 Inflammatory Breast Neoplasms 3 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 HER2-negative Breast Cancer 2 Carcinoma 2 Advanced Breast Cancer 2 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Neurotoxicity Syndromes 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Meningeal Carcinomatosis 1 Ketosis 1 HR+HER2- Breast Cancer 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 HER-2 Positive Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Drug-Related Side Effects and Adverse Reactions 1 Carcinoma, Transitional Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02061085 2025-06-08

MERIBEL

MedSIR

Phase 2 Completed

53 enrolled 11 charts

Breast Neoplasms, Ketosis, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡